Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM), Ironwood Pharma (IRWD) and Crispr Therapeutics AG (CRSP).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dexcom (DXCM)
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom yesterday and set a price target of $85.00. The company’s shares closed last Tuesday at $59.48.
According to TipRanks.com, Biegelsen is a 2-star analyst with an average return of
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $80.50, a 33.0% upside from current levels. In a report issued on April 20, TipRanks – xAI also upgraded the stock to Buy with a $73.00 price target.
See today’s best-performing stocks on TipRanks >>
Ironwood Pharma (IRWD)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Ironwood Pharma, with a price target of $5.00. The company’s shares closed last Tuesday at $4.67.
According to TipRanks.com, Bansal is a 5-star analyst with an average return of
Currently, the analyst consensus on Ironwood Pharma is a Moderate Buy with an average price target of $7.50, which is a 61.6% upside from current levels. In a report issued on April 20, TipRanks – xAI also reiterated a Hold rating on the stock with a $4.50 price target.
Crispr Therapeutics AG (CRSP)
Wells Fargo analyst Yanan Zhu maintained a Hold rating on Crispr Therapeutics AG yesterday and set a price target of $75.00. The company’s shares closed last Tuesday at $52.38.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $72.31 average price target, implying a 37.5% upside from current levels. In a report issued on May 4, TD Cowen also maintained a Hold rating on the stock with a $45.00 price target.
Read More on DXCM:
